Artivion (NYSE:AORT) Stock Price Up 8.2% - What's Next?

Key Points

• Artivion shares jumped 8.2% to about $28.46, with roughly 380,290 shares traded. The stock remains below its 200-day moving average of $30.92.
• Analyst sentiment is broadly positive: seven analysts rate the stock a Buy and one rates it a Sell, producing a consensus “Moderate Buy” rating and a $44.67 price target.
• Artivion exceeded quarterly expectations, reporting EPS of $0.13 versus estimates and revenue of $125.76 million versus $119.99 million expected. However, the company posted a slightly negative net margin, while an insider recently sold 44,001 shares under a pre-arranged trading plan.

Artivion, Inc. (NYSE:AORT - Get Free Report) shot up 8.2% during trading on Tuesday . The company traded as high as $28.56 and last traded at $28.4550. Approximately 380,290 shares traded hands during trading, a decline of 35% from the average daily volume of 589,164 shares. The stock had previously closed at $26.31.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on the stock. Citigroup restated a "market outperform" rating on shares of Artivion in a report on Tuesday, July 21st. Wall Street Zen lowered shares of Artivion from a "buy" rating to a "hold" rating in a research report on Saturday, April 25th. Needham & Company LLC reiterated a "buy" rating and issued a $44.00 price objective on shares of Artivion in a report on Monday, July 20th. Citizens Jmp lowered their target price on Artivion from $53.00 to $48.00 and set a "market outperform" rating for the company in a research note on Friday, May 8th. Finally, Stifel Nicolaus set a $45.00 price target on Artivion in a research report on Monday, June 1st. Seven analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company's stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $44.67.

Artivion Trading Up 8.3%

The company has a debt-to-equity ratio of 0.82, a current ratio of 3.47 and a quick ratio of 2.51. The firm's 50 day moving average price is $23.63 and its 200 day moving average price is $30.92. The stock has a market capitalization of $1.38 billion, a P/E ratio of -407.17 and a beta of 1.24.

Artivion (NYSE:AORT - Get Free Report) last announced its quarterly earnings results on Thursday, August 6th. The company reported $0.13 earnings per share (EPS) for the quarter. The company had revenue of $125.76 million for the quarter, compared to the consensus estimate of $119.99 million. Artivion had a positive return on equity of 6.07% and a negative net margin of 0.67%. As a group, equities research analysts expect that Artivion, Inc. will post 0.45 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, SVP Andrew M. Green sold 44,001 shares of Artivion stock in a transaction on Thursday, June 11th. The shares were sold at an average price of $20.70, for a total value of $910,820.70. Following the sale, the senior vice president owned 60,259 shares in the company, valued at $1,247,361.30. The trade was a 42.20% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 6.30% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Artivion

Several institutional investors and hedge funds have recently modified their holdings of AORT. Caitong International Asset Management Co. Ltd purchased a new position in shares of Artivion during the third quarter valued at about $27,000. Rockefeller Capital Management L.P. lifted its holdings in Artivion by 150.0% in the fourth quarter. Rockefeller Capital Management L.P. now owns 665 shares of the company's stock worth $30,000 after buying an additional 399 shares during the period. Larson Financial Group LLC lifted its holdings in Artivion by 148.5% in the fourth quarter. Larson Financial Group LLC now owns 942 shares of the company's stock worth $43,000 after buying an additional 563 shares during the period. Smartleaf Asset Management LLC boosted its position in Artivion by 47.7% during the 2nd quarter. Smartleaf Asset Management LLC now owns 1,667 shares of the company's stock valued at $52,000 after acquiring an additional 538 shares in the last quarter. Finally, KBC Group NV bought a new stake in Artivion during the 4th quarter valued at approximately $65,000. 86.37% of the stock is owned by hedge funds and other institutional investors.

About Artivion

Artivion, Inc NYSE: AORT is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source